Last updated on July 2019

Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: chronic phase chronic myelogenous leukemia
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  1. Have CP-CML and have received at least two prior tyrosine-kinase inhibitor (TKI) therapies and have demonstrated resistance to treatment OR have documented history of presence of T3151 mutation after receiving any number of prior TKI.
  2. The diagnosis of CML will be made using standard hematopathologic and cytogenetic criteria; CP-CML will be defined by all of the following:

i < 15% blasts in bone marrow. ii < 30% blasts plus promyelocytes in bone marrow. iii < 20% basophils in peripheral blood. iv Greater than or equal to (>=) 100 10^9/liter (L) platelets (>= 100,000/cubic millimeter [mm^3]).

v No evidence of extramedullary disease except hepatosplenomegaly. vi No prior diagnosis of accelerated phase (AP-CML), and blastic phase (BP-CML)

2. Cytogenetic assessment at screening must demonstrate the BCR-ABL1 fusion by presence of the t(9;22) Philadelphia chromosome.

i Variant translocations are only allowed provided they meet inclusion criterion 1d.

3. Resistance to prior TKI therapy is defined as follows (participants must meet at least 1 criterion):

i Three months after the initiation of prior TKI therapy: No cytogenetic response (> 95% Ph+) or failure to achieve CHR or new mutation.

ii Six months after the initiation of prior TKI therapy: BCR-ABL1IS >10% and/or Ph+ >65% or new mutation.

iii Twelve months after the initiation of prior TKI therapy: BCR ABL1IS >10% and/or Ph+ >35% or new mutation.

iv At any time after the initiation of prior TKI therapy, the development of a new BCR-ABL1 kinase domain mutation(s).

v At any time after the initiation of prior TKI therapy, the development of new clonal evolution vi At any time after the initiation of prior TKI therapy, the loss of CHR, or CCyR, or the confirmed loss of MMR in 2 consecutive tests, one of which has a BCR-ABL1IS transcript level of >=1% or new mutation.

4. > 1% of BCR-ABL1IS as shown by real-time polymerase chain reaction.

2. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

3. Have adequate renal function as defined by the following critera:

  • Serum creatinine <=1.5 upper limit of normal (ULN) for institution.
  • Estimated creatinine clearance >= 30 milliliter per minute (mL/min) (Cockcroft-Gault formula). 4. Have adequate hepatic function as defined by the following criteria:
  • Total serum bilirubin <=1.5 ULN, unless due to Gilbert's syndrome.
  • Alanine transaminase (ALT) <= 2.5 ULN, or <= 5 ULN if leukemic infiltration of the liver is present.
  • Aspartate transaminase (AST) <= 2.5 ULN, or <= 5 ULN if leukemic infiltration of the liver is present. 5. Have normal pancreatic status as defined by the following criterion:
    1. Serum lipase and amylase <= 1.5 ULN.
    2. Have normal QT interval corrected (Frederica) (QTcF) interval on screening electrocardiogram (ECG) evaluation, defined as QTcF of <= 450 milliseconds (ms) in males or <= 470 ms in females.
    3. Have recovered from toxicities related to prior anticancer therapy to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 grade <= 1.

Exclusion Criteria:

  1. Have used any approved TKIs or investigational agents within 2 weeks or 6 half-lives of the agent, whichever is longer, prior to receiving study drug.
  2. Received interferon, cytarabine, or immunotherapy within 14 days, or any other cytotoxic chemotherapy, radiotherapy, or investigational therapy within 28 days prior to receiving the first dose of ponatinib, or have not recovered (> grade 1 by NCI CTCAE, version 4.0) from AEs (except alopecia), due to agents previously administered.
  3. Have undergone autologous or allogeneic stem cell transplant <60 days prior to receiving the first dose of ponatinib; have any evidence of ongoing graft-versus-host disease (GVHD) or GVHD requiring immunosuppressive therapy or are being considered for stem cell transplant within 6-12 months of enrollment (note: ponatinib is not to be used as a bridge to stem cell transplant in this trial)
  4. Are taking medications with a known risk of Torsades de Pointes.
  5. Have clinically significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:
    • Any history of myocardial infarction (MI), unstable angina, cerebrovascular accident, or Transient Ischemic Attack (TIA).
    • Any history of peripheral vascular infarction, including visceral infarction.
    • Any revascularization procedure, including the placement of a stent.
    • Congestive heart failure (NYHA class III or IV) within 6 months prior to enrollment, or left ventricular ejection fraction (LVEF) less than lower limit of normal, per local institutional standards, within 6 months prior to enrollment.
    • History of clinically significant (as determined by the treating physician) atrial arrhythmia or any history of ventricular arrhythmia.
    • Venous thromboembolism, including deep venous thrombosis or pulmonary embolism, within 6 months prior to enrollment.
  6. Have uncontrolled hypertension (that is, >150 and >90 for systolic blood pressure (SBP) and diastolic blood pressure (DBP) respectively). Participants with hypertension should be under treatment at study entry to ensure blood pressure control. Those requiring 3 or more antihypertensive medications should be discussed with the medical monitor.
  7. Have poorly controlled diabetes defined as HbA1c values of > 7.5%. Participants with preexisting, well-controlled diabetes are not excluded.
    • Additional inclusion/exclusion criteria per protocol.

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.